Last edition
News about "schizophrenia "
Nxera Pharma to Get USD 35 Million from Neurocrine for Phase 2 Trial with NBI- '568
The NBI-’568-SCZ2028 dose-finding study met its primary endpoint for the once-daily 20 mg dose and was generally safe and well tolerated at all doses studied, supporting Neurocrine’s intentions to advance NBI- ‘568 into Phase 3 clinical trials in early 2025.
Schizophrenia | 03/09/2024 | By Aishwarya
Luye Pharma Gets US FDA Approval of ERZOFRI Extended-Release Injectable Suspension
Luye Pharma Group has announced that the US Food and Drug Administration (FDA) has approved the company's ERZOFRI (paliperidone palmitate) extended-release injectable suspension, for treating schizophrenia in adults and for treating schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Schizophrenia | 30/07/2024 | By Aishwarya | 137
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy